查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1662674

2030 年关节内粘稠补充疗法市场预测：按产品类型、来源、分销管道、应用和地区进行全球分析

Viscosupplementation Market Forecasts to 2030 - Global Analysis By Product Type (Hyaluronic Acid (HA) Injections, Non-Hyaluronic Acid Products and Other Product Types), Source, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球关节内粘稠补充疗法市场预计在 2024 年达到 54 亿美元，到 2030 年将达到 105 亿美元，预测期内的复合年增长率为 11.5%。关节内粘稠补充疗法治疗方法主要用于治疗膝关节骨关节炎 (OA)，其中凝胶状物质（通常是透明质酸 (HA)）注射到受影响的关节中以补充天然滑液。 HA透过恢復关节液的润滑性能来帮助减轻疼痛并提高活动能力。当止痛药和物理治疗等保守措施无法提供足够的缓解时，通常会使用这种治疗方法。此治疗方法创伤性极小，只需要在几週内注射几次即可。

根据美国疾病管制与预防中心2020年4月发表的《骨关节炎》论文显示，美国约有3,250万人美国骨关节炎。除此之外，62%的女性患有骨关节炎。

骨关节炎发生率增加

骨关节炎越来越常见，尤其是在膝盖等负重关节。患有这种疾病的人数日益增多，对有效治疗方法的需求也日益增加。关节内粘稠补充疗法是一种非侵入性手术治疗方法，已成为缓解症状和改善关节活动性的热门选择。由于骨关节炎影响了数百万人，预测期内对关节内粘稠补充疗法等可靠疗法的需求可能会持续成长。

缺乏报销政策

高昂的治疗费用和有限的保险覆盖范围可能会阻碍患者获得关节内粘稠补充疗法注射。缺乏全面的报销选择可能会阻止患者选择这种手术，特别是在医疗保险覆盖有限的地区。这种成本障碍可能会减缓关节内粘稠补充疗法疗法作为骨关节炎治疗方法的广泛应用。克服此类报销挑战对于确保更广泛的市场渗透至关重要。

微创手术的采用率不断提高

由于患者和医疗保健提供者优先考虑侵入性较小且恢復时间较短的治疗方法，因此关节内粘稠补充疗法疗法成为传统外科手术干预的引人注目的替代方案。该手术是非侵入性的，并且具有减轻疼痛和改善活动能力的潜力，使其成为治疗骨关节炎的良好选择。随着关节内粘稠补充疗法有望进一步获得认可并扩大市场占有率。

可能的副作用

关节内粘稠补充疗法会引起关节疼痛、肿胀和感染等副作用。这些副作用的风险可能会阻止一些患者选择关节内粘稠补充疗法作为治疗方法。此外，如果副作用无法妥善控制，可能会对治疗的声誉产生负面影响，并让患者和医疗保健提供者产生犹豫。解决安全问题和加强病患教育对于最大限度地减少这种威胁至关重要。

COVID-19 的影响

COVID-19 疫情关节内粘稠补充疗法。一方面，由于诊所关门、医疗资源重新分配，包括关节内粘稠补充疗法注射等选择性治疗程序的速度减慢。同时，此次疫情凸显了非手术治疗对治疗骨关节炎等慢性病的重要性，随着医疗系统的适应，需求将会恢復。随着人们越来越重视减少就诊次数和促进门诊治疗，关节内粘稠补充疗法很可能在后疫情时代作为首选治疗方法持续增长。

预计预测期内透明质酸（HA）注射市场规模将达到最大。

预计透明质酸 (HA) 注射剂将在预测期内占据最大的市场占有率，因为它具有恢復滑液、提供润滑和减少骨关节炎关节发炎的能力。其已被证实的有效性和在关节内粘稠补充疗法中的长期使用关节内粘稠补充疗法成为患者和医疗保健提供者的首选。作为最成熟、应用最广泛的关节内粘稠补充疗法，HA 注射疗法预计将在未来几年占据市场主导地位。

预计预测期内非动物性食品部分将以最高的复合年增长率成长。

由于人们对动物源产品的潜在风险的担忧日益增加，预计非动物源部分将在预测期内呈现最高的成长率，使得非动物源透明质酸成为患者更具吸引力的选择。这些产品适合对动物性治疗有过敏反应或有道德问题的患者。非动物关节内粘稠补充疗法产品的需求正在增长，因为它们被认为更安全、更永续，为製造商提供了市场扩张机会并满足了消费者的偏好。

比最大的地区

在预测期内，预计北美将占据最大的市场占有率，这得益于人们对骨关节炎治疗的高度认识和高昂的医疗支出。预计北美的需求将持续存在，因为北美民众关节内粘稠补充疗法有强烈的偏好，而且老龄化人口众多。此外，预计美国和加拿大领先製造商和研究机构的存在将在整个预测期内推动关节内粘稠补充疗法市场的创新和成长。

复合年增长率最高的地区

预计预测期内亚太地区将呈现最高的复合年增长率。快速的都市化、医疗保健机会的增加以及人口老化导致该地区骨关节炎的盛行率上升。在中国、印度和日本等国家，由于医疗意识的增强和医疗设施的改善，关节内粘稠补充疗法的采用正在增长。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球关节内粘稠补充疗法市场（依产品类型划分）

  • 介绍
  • 透明质酸 (HA) 注射
    • 单次注射产品
    • 多种注塑产品
    • 五注塑产品
  • 不含玻尿酸的产品
    • 胶原蛋白注射剂
    • 富血小板血浆
    • 干细胞注射
  • 其他的

6. 全球关节内粘稠补充疗法市场（依来源划分）

  • 介绍
  • 动物来源
  • 非动物来源

7. 全球关节内粘稠补充疗法市场按分销管道划分

  • 介绍
  • 直接销售
  • 诊所
  • 零售药局和药局
  • 网路药局和电子商务平台
  • 其他的

8. 全球关节内粘稠补充疗法市场（按应用）

  • 介绍
  • 骨关节炎
  • 创伤性关节炎
  • 类风湿性关节炎
  • 膝关节骨关节炎
  • 其他的

9. 全球关节内粘稠补充疗法市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Anika Therapeutics, Inc.
  • Aptissen
  • Bioventus LLC
  • Chugai Pharmaceuticals Co., Ltd.
  • DePuy Synthes
  • F.Hoffmann-La Roche Ltd.
  • Ferring Pharmaceuticals BV
  • Fidia Farmaceutici SpA
  • Johnson & Johnson Services, Inc.
  • LG Life Sciences Ltd.
  • Lifecore Biomedical
  • OrthogenRx Inc.
  • Sanofi
  • Seikagaku Corp.
  • Smith & Nephew PLC
  • Zimmer Biomet
Product Code: SMRC28535

According to Stratistics MRC, the Global Viscosupplementation Market is accounted for $5.4 billion in 2024 and is expected to reach $10.5 billion by 2030 growing at a CAGR of 11.5% during the forecast period. Viscosupplementation is a medical treatment for osteoarthritis (OA), primarily in the knee that involves injecting a gel-like substance, typically hyaluronic acid (HA), into the affected joint to supplement the natural synovial fluid. HA helps reduce pain and improve mobility by restoring the fluid's lubricating properties. This treatment is often used when conservative measures like pain medications or physical therapy have not provided sufficient relief. The procedure is minimally invasive, requiring just a few injections spaced over several weeks.

According to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis.

Market Dynamics:

Driver:

Rising incidence of osteoarthritis

Osteoarthritis is becoming more prevalent, especially in weight-bearing joints like the knee. The increasing number of people suffering from this condition is creating a growing demand for effective treatment options. Viscosupplementation, offering a non-invasive alternative to surgery, has gained popularity as an option to alleviate symptoms and improve joint mobility. With osteoarthritis affecting millions, the need for reliable therapies, such as viscosupplementation, will continue to expand during the forecast period.

Restraint:

Lack of reimbursement policies

The high cost of the treatment and limited insurance coverage can hinder patient access to viscosupplementation injections. The absence of comprehensive reimbursement options may deter patients from opting for the procedure, especially in areas with stricter healthcare policies. This cost-related barrier can slow the widespread adoption of viscosupplementation as a treatment for osteoarthritis. Overcoming these reimbursement challenges will be crucial to ensuring broader market penetration.

Opportunity:

Increasing adoption of minimally invasive procedures

As patients and healthcare providers prioritize less invasive treatment options with quicker recovery times, viscosupplementation offers a compelling alternative to traditional surgical interventions. The procedure's non-invasive nature, coupled with its potential to reduce pain and improve mobility, positions it as a favorable choice for managing osteoarthritis. With the growing trend toward outpatient, minimally invasive procedures, viscosupplementation is expected to gain further traction, expanding its market share.

Threat:

Potential for adverse reactions

Viscosupplementation procedure can lead to side effects such as joint pain, swelling, or infection. The risk of these reactions may discourage some patients from choosing viscosupplementation as a treatment option. Additionally, adverse reactions, if not properly managed, could negatively impact the reputation of the treatment, creating hesitancy among both patients and healthcare providers. Addressing safety concerns and improving patient education is essential for minimizing this threat.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the viscosupplementation market. On one hand, lockdowns and healthcare resource reallocations slowed elective procedures, including viscosupplementation injections, due to restricted access to clinics. On the other hand, the pandemic highlighted the importance of non-surgical treatments for managing chronic conditions like osteoarthritis, leading to a rebound in demand as healthcare systems adapted. With a growing focus on reducing hospital visits and promoting outpatient care, viscosupplementation may see sustained growth as a preferred treatment in the post-pandemic era.

The hyaluronic acid (HA) injections segment is expected to be the largest during the forecast period

The hyaluronic acid (HA) injections segment is expected to account for the largest market share during the forecast period owing to its ability to restore synovial fluid, providing lubrication and reducing inflammation in osteoarthritis -affected joints. Its proven effectiveness and long-standing use in viscosupplementation have made it the preferred choice for both patients and healthcare providers. As the most established and widely used form of viscosupplementation, the HA injections segment is anticipated to dominate the market in the coming years.

The non-animal source segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the non-animal source segment is predicted to witness the highest growth rate due to increasing concerns over the potential risks of animal-derived products, non-animal-based hyaluronic acid offers a more attractive option for patients. These products cater to individuals who may have allergies or ethical concerns related to animal-based treatments. The demand for non-animal sourced viscosupplementation products is rising as they are perceived to be safer and more sustainable, offering manufacturers a growing opportunity to expand their market reach and meet consumer preferences.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to high awareness of osteoarthritis treatments, and significant healthcare spending. With a strong preference for non-invasive treatments like viscosupplementation, North America's large aging population will drive continued demand. Furthermore, the presence of leading manufacturers and research institutions in the United States and Canada will support innovation and the growth of the viscosupplementation market throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid urbanization, increasing healthcare access, and a growing elderly population are contributing to the rising prevalence of osteoarthritis in this region. Countries like China, India, and Japan are seeing greater adoption of viscosupplementation due to rising healthcare awareness and improved medical facilities.

Key players in the market

Some of the key players in Viscosupplementation market include Anika Therapeutics, Inc., Aptissen, Bioventus LLC, Chugai Pharmaceuticals Co., Ltd., DePuy Synthes, F.Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V., Fidia Farmaceutici S.p.A, Johnson & Johnson Services, Inc., LG Life Sciences Ltd., Lifecore Biomedical, OrthogenRx Inc., Sanofi, Seikagaku Corp., Smith & Nephew PLC and Zimmer Biomet.

Key Developments:

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.

In December 2024, Smith+Nephew announced its CORIOGRAPH Pre-Op Planning and Modeling Services are now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration.

Product Types Covered:

  • Hyaluronic Acid (HA) Injections
  • Non-Hyaluronic Acid Products
  • Other Product Types

Sources Covered:

  • Animal Source
  • Non-Animal Source

Distribution Channels Covered:

  • Direct Sales
  • Clinics
  • Retail Pharmacies & Drugstores
  • Online Pharmacies & E-commerce Platforms
  • Other Distribution Channels

Applications Covered:

  • Osteoarthritis
  • Post-Traumatic Arthritis
  • Rheumatoid Arthritis
  • Knee Osteoarthritis
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viscosupplementation Market, By Product Type

  • 5.1 Introduction
  • 5.2 Hyaluronic Acid (HA) Injections
    • 5.2.1 Single-Injection Products
    • 5.2.2 Multiple-Injection Products
    • 5.2.3 Five-Injection Products
  • 5.3 Non-Hyaluronic Acid Products
    • 5.3.1 Collagen-Based Injections
    • 5.3.2 Platelet-Rich Plasma
    • 5.3.3 Stem Cell-Based Injections
  • 5.4 Other Product Types

6 Global Viscosupplementation Market, By Source

  • 6.1 Introduction
  • 6.2 Animal Source
  • 6.3 Non-Animal Source

7 Global Viscosupplementation Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Clinics
  • 7.4 Retail Pharmacies & Drugstores
  • 7.5 Online Pharmacies & E-commerce Platforms
  • 7.6 Other Distribution Channels

8 Global Viscosupplementation Market, By Application

  • 8.1 Introduction
  • 8.2 Osteoarthritis
  • 8.3 Post-Traumatic Arthritis
  • 8.4 Rheumatoid Arthritis
  • 8.5 Knee Osteoarthritis
  • 8.6 Other Applications

9 Global Viscosupplementation Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Anika Therapeutics, Inc.
  • 11.2 Aptissen
  • 11.3 Bioventus LLC
  • 11.4 Chugai Pharmaceuticals Co., Ltd.
  • 11.5 DePuy Synthes
  • 11.6 F.Hoffmann-La Roche Ltd.
  • 11.7 Ferring Pharmaceuticals B.V.
  • 11.8 Fidia Farmaceutici S.p.A
  • 11.9 Johnson & Johnson Services, Inc.
  • 11.10 LG Life Sciences Ltd.
  • 11.11 Lifecore Biomedical
  • 11.12 OrthogenRx Inc.
  • 11.13 Sanofi
  • 11.14 Seikagaku Corp.
  • 11.15 Smith & Nephew PLC
  • 11.16 Zimmer Biomet

List of Tables

  • Table 1 Global Viscosupplementation Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Viscosupplementation Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Viscosupplementation Market Outlook, By Hyaluronic Acid (HA) Injections (2022-2030) ($MN)
  • Table 4 Global Viscosupplementation Market Outlook, By Single-Injection Products (2022-2030) ($MN)
  • Table 5 Global Viscosupplementation Market Outlook, By Multiple-Injection Products (2022-2030) ($MN)
  • Table 6 Global Viscosupplementation Market Outlook, By Five-Injection Products (2022-2030) ($MN)
  • Table 7 Global Viscosupplementation Market Outlook, By Non-Hyaluronic Acid Products (2022-2030) ($MN)
  • Table 8 Global Viscosupplementation Market Outlook, By Collagen-Based Injections (2022-2030) ($MN)
  • Table 9 Global Viscosupplementation Market Outlook, By Platelet-Rich Plasma (2022-2030) ($MN)
  • Table 10 Global Viscosupplementation Market Outlook, By Stem Cell-Based Injections (2022-2030) ($MN)
  • Table 11 Global Viscosupplementation Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 12 Global Viscosupplementation Market Outlook, By Source (2022-2030) ($MN)
  • Table 13 Global Viscosupplementation Market Outlook, By Animal Source (2022-2030) ($MN)
  • Table 14 Global Viscosupplementation Market Outlook, By Non-Animal Source (2022-2030) ($MN)
  • Table 15 Global Viscosupplementation Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 16 Global Viscosupplementation Market Outlook, By Direct Sales (2022-2030) ($MN)
  • Table 17 Global Viscosupplementation Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 18 Global Viscosupplementation Market Outlook, By Retail Pharmacies & Drugstores (2022-2030) ($MN)
  • Table 19 Global Viscosupplementation Market Outlook, By Online Pharmacies & E-commerce Platforms (2022-2030) ($MN)
  • Table 20 Global Viscosupplementation Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 21 Global Viscosupplementation Market Outlook, By Application (2022-2030) ($MN)
  • Table 22 Global Viscosupplementation Market Outlook, By Osteoarthritis (2022-2030) ($MN)
  • Table 23 Global Viscosupplementation Market Outlook, By Post-Traumatic Arthritis (2022-2030) ($MN)
  • Table 24 Global Viscosupplementation Market Outlook, By Rheumatoid Arthritis (2022-2030) ($MN)
  • Table 25 Global Viscosupplementation Market Outlook, By Knee Osteoarthritis (2022-2030) ($MN)
  • Table 26 Global Viscosupplementation Market Outlook, By Other Applications (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.